SERS-Based Immunoassay Enhanced with Silver Probe for Selective Separation and Detection of Alzheimer’s Disease Biomarkers

PURPOSE: Developing a sensitive SERS-based method to quantitatively detect serum biomarkers (Aβ1-42 and P-Tau-181) for the early diagnosis of Alzheimer’s disease (AD). METHODS: In this study, a novel SERS-based sandwich immunoassay, which consists of tannin-capped silver nanoparticles and magnetic graphene oxide (Fe(3)O(4)@GOs), was developed. We firstly applied this method for the detection of protein standards in buffer solution, obtaining the regression equation. Then, its potential value on real serum samples of AD was further explored. RESULTS: The detection linear range of Aβ1-42 and P-Tau-181 protein standards were observed to range from 100 pg mL(−1) to 10 fg mL(−1), 100 pg mL(−1) to 1 fg mL(−1) respectively. We finally explored clinical application of the proposed method in 63 serum samples. As a result, P-tau-181 differentiated AD from non-AD dementia patients (AUC = 0.770), with a more favored ROC than Aβ1-42 (AUC = 0.383). CONCLUSION: The developed SERS-based immunoassay is successfully applied to the determination of Aβ1-42 and P-Tau-181 in human serum specimens, which provides a promising tool for the early diagnosis of AD.